Intensity Therapeutics Inc (INTS)

Currency in USD
4.000
0.000(0.00%)
Closed·
4.030+0.030(+0.75%)
·
Advertisement
INTS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.0004.120
52 wk Range
0.40743.500
Key Statistics
Prev. Close
4
Open
4.12
Day's Range
4-4.12
52 wk Range
0.407-43.5
Volume
9.97K
Average Volume (3m)
42.72K
1-Year Change
-40.6748%
Book Value / Share
3.41
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
INTS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
19.333
Upside
+383.33%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings downwards for the upcoming period

Intensity Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 19.333
(+383.33% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy7.00+75.00%-Maintain19/08/2026
Benchmark
Buy12.00+200.00%12.00Maintain20/05/2026
Freedom Capital Markets
Buy20.00+400.00%-Upgrade30/03/2026

Intensity Therapeutics Inc Earnings Call Summary for Q2/2026

  • Intensity Therapeutics posted Q2 2026 adjusted loss of $1.11/share, missing analyst estimates of $0.87/share by 27.6%.
  • Shares declined 4.62% to $4.092 in premarket trading; stock remains volatile with beta of 3.03 and market cap of $11.6M.
  • Company faces ongoing cash burn concerns requiring additional funding to advance clinical cancer trial programs.
  • Analyst price targets range $12-$32; stock trades below 52-week high of $43.5 but maintains strong current ratio of 4.86.
Last Updated: 11/08/2026, 13:58
Read Full Transcript

Earnings

Latest Release
11/08/2026
EPS / Forecast
-1.11 / -0.87
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare INTS to Peers and Sector

Metrics to compare
INTS
Peers
Sector
Relationship
P/E Ratio
−1.2x−2.4x−0.4x
PEG Ratio
−0.02−0.030.00
Price/Book
1.4x3.5x2.6x
Price / LTM Sales
-17.5x3.1x
Upside (Analyst Target)
337.5%90.9%49.0%
Fair Value Upside
Unlock4.2%7.1%Unlock

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
55.89K1.71%223.56K
Other Institutional Investors
796.21K24.39%3.18M
Public Companies & Retail Investors
2.41M73.90%9.65M
Total
3.26M100.00%13.06M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Kingsbury Capital Investment Advisors LLC15.21%496,4931,986
Vcapital Intensity, Llc2.47%80,635323

People Also Watch

0.144
BRTX
-28.76%
1.9000
TC
-5.47%
29.43
KMT
-0.07%
3.0600
FEMY
-1.29%
49.550
LMB
+2.00%

FAQ

What Is the Intensity Therapeutics (NASDAQ: INTS) Share Price Today?

The Intensity Therapeutics stock price today is 4.000 USD.

What Stock Exchange Does Intensity Therapeutics (INTS) Trade On?

Intensity Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Intensity Therapeutics?

The stock symbol (also called a 'ticker') for Intensity Therapeutics is "INTS."

What Is the Current Intensity Therapeutics Market Capitalisation?

As of today, Intensity Therapeutics (NASDAQ: INTS) market cap is 13.060M USD.

What Is Intensity Therapeutics's (INTS) Earnings Per Share (TTM)?

The Intensity Therapeutics EPS is currently -4.799 (Trailing Twelve Months).

When Is the Next Intensity Therapeutics Earnings Date?

Intensity Therapeutics's next earnings report will be released on 17/11/2026.

Is INTS a Buy or Sell From a Technical Analyst Perspective?

Based on today's Intensity Therapeutics moving averages and other technical indicators, the daily buy/sell signal for INTS stock is Strong Sell.

How Many Times Has Intensity Therapeutics Stock Split?

Intensity Therapeutics has split 2 times. (See the INTS stock split history page for full effective split date and price information.)

What is the current trading status of Intensity Therapeutics (NASDAQ: INTS)?

As of 03/09/2026, Intensity Therapeutics (INTS) is trading at a share price of 4.000 USD, with a previous close of 4.000 USD. The stock has fluctuated within a day range of 4.000 USD to 4.120 USD, while its 52-week range spans from 0.407 USD to 43.500 USD.

What Is Intensity Therapeutics (INTS) Price Target According to Analysts?

The average 12-month price target for Intensity Therapeutics is 19.333 USD, with a high estimate of 32 USD and a low estimate of 7 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +383.33% Upside potential.

What Is the INTS Premarket Price?

INTS's last pre-market stock price is 4.120 USD. The pre-market share volume is 110.000, and the stock has decreased by 0.120, or 3.000%.

What Is the INTS After Hours Price?

INTS's last after hours stock price is 4.030 USD, the stock has decreased by 0.030, or 0.750%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.